ANSOLYSEN Drug Patent Profile
✉ Email this page to a colleague
When do Ansolysen patents expire, and when can generic versions of Ansolysen launch?
Ansolysen is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in ANSOLYSEN is pentolinium tartrate. Additional details are available on the pentolinium tartrate profile page.
Summary for ANSOLYSEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 22 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ANSOLYSEN at DailyMed |
US Patents and Regulatory Information for ANSOLYSEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wyeth Ayerst | ANSOLYSEN | pentolinium tartrate | INJECTABLE;INJECTION | 009372-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |